Clinical positioning
Lower concentration cannabinoid-rich oil for inflammatory pain and mobility-support discussions.
Clinical use lens
Inflammation-first entry oilA practical starting choice when pain is linked with stiffness, inflammatory tone or mobility limitation.
Video brochure
Cannoflam™ in inflammation and pain
Routes of administration, mechanism of action, clinical settings and safety, dosing and titration.
All 5 videos
Cannoflam™ in inflammation and pain2:12 · Routes of administration, mechanism of action, clinical settings and safety, dosing and titration.
Cannoflam™ dose titration guide1:38 · Bottle strength, target dose, starting low and key points.
Homeostasis through Cannoflam™2:51 · Mechanism briefing: ECS and inflammation, the evidence, five-step titration, a worked example and pre-dose screening.
Cannoflam™ multi-route anti-inflammatory2:54 · How it compares, routes, where it fits, a five-step quick start, a worked example and pre-dose screening.
Cannoflam™ dose titration, alternate cut1:39 · Bottle strength, target dose, how to titrate and key points.
Doctor-facing educational video. It does not replace the product label, this monograph or clinical judgement.
Indication fit
Clinical highlights
Mechanism map
Administration & dosing
Dose framework
X = body weight in kilograms≤ X/2 mgGrade-guided range
X–10X mg
First dose must never exceed X/2 mg total cannabinoids (equivalent to ≤0.5 mg/kg when X is body weight in kg). Further titration may move within X to 10X mg total cannabinoids only after tolerance and response review.
Indication grade
- Grade 1–10: set by indication severity, pain/inflammation burden, ESR, CRP and symptom trajectory.
- Adjust for age, frailty, secondary conditions, hepatic/renal risk, concurrent medicines and tolerance.
- Use follow-up response to hold, increase, reduce or discontinue.
Titration model
- Incremental: gradual upward titration until response / tolerability.
- Incremental–decremental: step up, then reduce to minimum effective maintenance.
- Microdosing: very low divided exposure for sensitive, elderly or polypharmacy patients.
Administration
- Oral / sublingual / with suitable carrier as per physician direction and product format.
- Prefer consistent timing; document relation to food, sleep, pain peak, appetite or protocol goal.
- Document dose, route, time, food/carrier, indication grade, ESR/CRP or relevant markers, adverse effects and follow-up plan.
- Monitor sedation, dizziness, GI tolerance, cognition, drug interactions and functional response.
Full titration walkthrough: physician dosage guide.
Doctor use notes & safety boundary
Doctor use notes
- Start low and titrate by clinical context, tolerability and symptom severity.
- Track response, co-medications, sedation, GI tolerance and follow-up outcome.
- Document dose, timing, duration, indication and review plan.
Safety boundary
- For registered medical practitioners only
- Select dose by clinical context and tolerability
- Monitor sedation, interactions and follow-up response
- Not for direct patient promotion
Formula / ingredients
| Ingredient | Botanical / base | Part | Qty |
|---|---|---|---|
| Vijaya leaves | Cannabis Sativa Linn | Leaves | 10% |
| Coconut Oil | Cocos Nucifera | — | 90% |
Pack / MRP
| Pack | Strength | MRP |
|---|---|---|
| 10 ml (1 g) | 1000mg total cannabinoids≈ 5 mg/drop | ₹550 |
| 30 ml (3 g) | 3000mg total cannabinoids≈ 5 mg/drop | ₹1,299 |
Pack / MRP summary: 10 ml (1 g) ₹550 (1000mg) · 30 ml (3 g) ₹1,299 (3000mg)
Audited research links
| Audited reference fit | Clinical logic | Source |
|---|---|---|
| CBD / cannabinoids ✓ Pain/inflammation checkedPMC full textScientific context Cannabidiol as a Treatment for Arthritis and Joint Pain | Arthritis and joint pain research support | Open ↗ |
| CBD ✓ Pain/inflammation checkedPMC full textMechanistic rationale CBD for Pain Treatment: Focus on Pharmacology and Mechanism of Action | Pain pharmacology and CB2/TRPV1/5-HT1A mechanisms | Open ↗ |
| Cannabis active compounds ✓ Pain/inflammation checkedPMC full textMechanistic rationale Medical Cannabis Activity Against Inflammation: Active Compounds and Mechanisms | Anti-inflammatory active-compound mechanisms | Open ↗ |
| MCT / lipid carrier ✓ Scientific fit checkedPMC full textScientific context Inclusion of Medium-Chain Triglyceride in Lipid-Based Formulations for Cannabidiol | CBD/MCT lipid-formulation and carrier-solubilisation context | Open ↗ |



